Hancock Whitney Corp Alpine Immune Sciences, Inc. Transaction History
Hancock Whitney Corp
- $2.88 Billion
- Q1 2024
Shares
3 transactions
Others Institutions Holding ALPN
# of Institutions
185Shares Held
62MCall Options Held
158KPut Options Held
199K-
Decheng Capital LLC Menlo Park, CA8.32MShares$044.22% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.78MShares$02.76% of portfolio
-
Black Rock Inc. New York, NY3.58MShares$00.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.13MShares$06.52% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.08MShares$00.01% of portfolio
About ALPINE IMMUNE SCIENCES, INC.
- Ticker ALPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 44,006,700
- Description
- Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28...